Debut Biotechnology Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
87
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$20M
- Investors
-
24
Debut Biotechnology General Information
Description
Developer of a biotechnology platform designed to create climate-positive products. The company offers features such as research and development capabilities focused on sustainable practices, partnerships with organizations to promote ecological balance, and a commitment to creating environmentally friendly alternatives, fostering product performance rooted in science, enabling businesses to reduce their carbon footprint while contributing positively to environmental and social well-being.
Contact Information
Website
www.debutbiotech.comCorporate Office
- 10210 Campus Point Drive
- San Diego, CA 92121
- United States
Corporate Office
- 10210 Campus Point Drive
- San Diego, CA 92121
- United States
Debut Biotechnology Timeline
Debut Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 26-Aug-2025 | $20M | Completed | Generating Revenue | ||
| 5. Early Stage VC (Series B1) | 19-Oct-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B2) | 19-Nov-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 12-Aug-2021 | Completed | Generating Revenue | |||
| 2. Grant | 15-Sep-2020 | $1M | $2.61M | Completed | Generating Revenue | |
| 1. Seed Round | 06-Jan-2020 | $2.61M | $2.61M | Completed | Generating Revenue |
Debut Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B-2 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Seed-2 | 144,114 | $0.000100 | 8% | $5.3 | $5.3 | 1x | $5.3 | 3.64% |
| Seed-1 | 377,221 | $0.000100 | 8% | $4.24 | $4.24 | 1x | $4.24 | 9.52% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Debut Biotechnology Comparisons
Industry
Financing
Details
Debut Biotechnology Competitors (6)
One of Debut Biotechnology’s 6 competitors is Novonesis, a Corporation company based in Lyngby, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novonesis | Corporation | Lyngby, Denmark | ||||
| Codexis | Formerly VC-backed | Redwood City, CA | ||||
| BellBrook Labs | Venture Capital-Backed | Madison, WI | ||||
| Conagen | Corporate Backed or Acquired | Bedford, MA | ||||
| Enginzyme | Venture Capital-Backed | Solna, Sweden |
Debut Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Debut Biotechnology Patents
Debut Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026096782-A1 | Bioproduction of tetrahydrocurcumin and tetrahydrodemethoxycurcumin | Pending | 01-Nov-2024 | ||
| WO-2026096786-A1 | Methods and systems for preparing panthenol | Pending | 31-Oct-2024 | ||
| WO-2026085447-A1 | Methods and systems for preparing retinol | Pending | 18-Oct-2024 | ||
| WO-2026072644-A1 | Bioproduction of kermesic acid and carminic acid | Pending | 25-Sep-2024 | ||
| AU-2024411933-A1 | Methods and compositions for bioproduction of pectolinarigenin | Pending | 29-Dec-2023 | C12N9/0071 |
Debut Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Debut Biotechnology Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EDBI | Venture Capital | Minority | ||
| L'Oréal UK | Corporation | Minority | ||
| SiteGround Capital | Family Office | Minority | ||
| Wealthberry | Corporation | Minority | ||
| BOLD (Business Opportunities for L'Oréal Development) | Corporate Venture Capital | Minority |
Debut Biotechnology FAQs
-
When was Debut Biotechnology founded?
Debut Biotechnology was founded in 2019.
-
Where is Debut Biotechnology headquartered?
Debut Biotechnology is headquartered in San Diego, CA.
-
What is the size of Debut Biotechnology?
Debut Biotechnology has 87 total employees.
-
What industry is Debut Biotechnology in?
Debut Biotechnology’s primary industry is Biotechnology.
-
Is Debut Biotechnology a private or public company?
Debut Biotechnology is a Private company.
-
What is Debut Biotechnology’s current revenue?
The current revenue for Debut Biotechnology is .
-
How much funding has Debut Biotechnology raised over time?
Debut Biotechnology has raised $89.3M.
-
Who are Debut Biotechnology’s investors?
EDBI, L'Oréal UK, SiteGround Capital, Wealthberry, and BOLD (Business Opportunities for L'Oréal Development) are 5 of 24 investors who have invested in Debut Biotechnology.
-
Who are Debut Biotechnology’s competitors?
Novonesis, Codexis, BellBrook Labs, Conagen, and Enginzyme are some of the 6 competitors of Debut Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
